



ROLE OF FREE RADICALS AND EFFECTIVENESS OF ANTIOXIDANTS IN PATIENTS WITH OSFM AND OLP- A SYSTEMATIC REVIEW.

DR. VEENA NAIK^{*1}, DR. SAURABH PRAKASH², DR. LIRIN ANN THOMAS³

¹*Senior Lecturer, Dept. of Oral Medicine and Diagnostic Radiology, Faculty of Dentistry, AIMST University, Semeling, 08100 Bedong, Kedah Darul Aman- Malaysia*

²*Senior Lecturer, Dept. of Orthodontics, Faculty of Dentistry, AIMST University, Semeling, 08100 Bedong, Kedah Darul Aman – Malaysia*

³*Lecturer, Dept. of Orthodontics, Faculty of Dentistry, AIMST University, Semeling, 08100 Bedong, Kedah Darul Aman - Malaysia*

ABSTRACT

The aim of the present study is to update the evidence of antioxidants in treating oral premalignant diseases and it's effectiveness; Data sources: automated searches of Medline, Pubmed, and the Cochrane Library were conducted; additional searches of main oral medicine journals were done manually using the keywords oral submucous fibrosis (OSF), Oral leukoplakia (OLP), treatment and antioxidants. Inclusion criteria: Surveys; randomised controlled studies (RCTs), observational studies, or case series reports that encompassed individuals of any age with confirmed diagnosis of OSF and OLP clinically and histopathologically. Types of interventions excluded were treatments with only habit intervention, surgical procedures, medical treatments (i.e. systemic, submucosal injection or topical agents), or physical therapy. 23 studies related to OLP and 15 studies related to OSF, were identified for inclusion. The authors were thoughtful in interpreting their conclusions. Treatment options included oral lycopene, oral lycopene with intralesional corticosteroids or an oral placebo; oral and topical curcumin, oral levamisole; multivitamins and oral beta carotene. Various objective and subjective outcomes improved with antioxidants, whereas some studies showed regression and malignancies. Use of antioxidants show some promise but there are no studies indicating the effectiveness of particular antioxidants or their combinations to be superior. Thus we conclude that current evidence for the benefit of antioxidants to manage OSF and OLP is weak.

KEYWORDS: *Oral submucous fibrosis (OSF), Oral leukoplakia (OLP), Antioxidants, Curcumin, Lycopene.*

INTRODUCTION

The past twenty years have seen an explosion of interest in free radicals, as their pivotal role in both chemistry and biology has come to light. The ability to utilize oxygen has provided humans with the benefit of metabolizing nutrients. Oxygen is a highly reactive atom that is capable of becoming part of potentially damaging molecules commonly called "free radicals." Oral cells are uniquely susceptible to free radical damage because the mucus membranes allow rapid absorption of substances across their surfaces. Direct exposure to noxious substances in the mouth further exacerbates the problem. Alcohol, nicotine from tobacco products, and dental materials such as hydrogen peroxide for bleaching, dental cements,

composite fillings, and dental implants all increase free radicals resulting in cell damage¹. Free radicals have been implicated in the etiology of large number of major diseases. They can adversely alter many crucial biological molecules leading to loss of form and function. Such undesirable changes in the body can lead to diseased conditions². Oral cavity is exposed to lot of carcinogens and is prone to develop precancerous lesions and conditions which may turn to oral cancer. Oral cancer is a disease with high morbidity and mortality, and is the sixth commonest cancer in the world (Parkin et al, 1993)³. Its incidence is particularly high in India, some other countries in Asia, and certain places in the Western hemisphere, e.g., parts of France and Brazil. Dietary substitute play a vital role in prevention of oral cancer, potentially malignant

disorders like leukoplakia, lichen planus, oral submucous fibrosis, burning mouth syndrome, dental caries, strengthening the bond strength of orthodontic brackets, aids in bone healing and treating periimplantitis. Oral submucous fibrosis (OSF) is a chronic inflammatory disease, which has been categorised by WHO as one of the potentially malignant disorders (WHO workshop, 2005). Malignant transformation rate of OSMF is 7.6 % over a period of 10 years has been reported³. And according to Warnakulasuriya et al.⁴, the new concept of OLP shall acknowledge white lesions with questionable risk of being an OLP. Downer and Petti found an annual oral cancer incidence rate attributable to leukoplakia between 6.2 and 29.1 cases per 100,000 people⁵. Oral leukoplakia and OSF is relatively common oral lesion that, in an erratic proportion of cases, undergoes malignant transformation. Hence, leukoplakia and OSF should be considered a severe health problem.

DISCUSSION

Free radicals

Free radicals are an unstable atom or molecule that contains one or more unpaired electrons in their valence shell (Fig 1)¹². The first free radical identified, was triphenylmethyl radical by Moses Gomberg in 1900 at the University of Michigan⁶. Free radicals are produced during, Normal cellular activities like liver detoxification, Immune reactions and ETC (electron transport chain) reactions, or in Pathological events like ionizing radiation, toxic chemicals and tissue ischemia or they are produced in Disease conditions⁷. At low or moderate levels of concentration, ROS (reactive oxygen species) participate in the biosynthesis of

molecules. At high concentrations; they generate oxidative stress and nitrosative stress that can damage all cell structures⁸.

Oxidative stress

In a biological context, reactive oxygen species (ROS) and reactive nitrogen species (RNS) are formed as a natural byproduct of the normal metabolism of oxygen and have important roles in cell signaling and homeostasis⁹. However, during environmental stress (e.g., UV or heat exposure), ROS levels can increase dramatically opposing body's antioxidant defense mechanisms leading to Oxidative stress. Cellular constituents of our body are altered in oxidative stress conditions, resulting in various diseases. This can be effectively neutralized by enhancing cellular defense in the form of antioxidants¹⁰. The generation of ROS begins with rapid uptake of oxygen, activation of NADPH oxidase, and the production of the superoxide anion radical (O_2^-)¹¹.

Antioxidant

Today, the entire world is suffering a rise in chronic health complications. Diets rich in fruits and vegetables have protective effect against a variety of diseases. The primary nutrients provide protection afforded by fruit and vegetables are the "Antioxidants"⁸. An antioxidant is a molecule which inhibits the oxidation reaction; terminate the chain reaction caused by free radicals of oxidation reaction, preventing cell damage or death of the cells. Ideal antioxidants have no harmful effects, are effective in low concentration, are fat soluble, readily available and do not contribute to objectionable flavor, odor or color to the fat⁹.




Figure 1
Formation of Free Radicals

Mechanism of action

Reactive oxygen species can cause tissue damage by a variety of different mechanism which include^{13,14}

- DNA damage
- Lipid peroxidation (through activation of cyclogenase and lipooxygenase pathway)
- Protein damage, including gingival hyaluronic acid and proteoglycans
- Oxidation of important enzymes, e.g. Antiprotease such as; antitrypsin
- Stimulation of pro inflammatory cytokine release by
- Monocytes and macrophages by depleting intracellular thiol compounds and activating nuclear factor.

Mechanisms by which antioxidants may offer protection

- Prevention of formation of free radicals
- Interception of free radicals
- Facilitating the repair
- Providing a favourable environment

Saliva is the considered oral cavity's first level of defense system against oxidative stress. In healthy individuals, the total antioxidant capacity of saliva is sufficient to maintain homeostasis by neutralizing mild oxidative damage. When that equilibrium is disturbed by an overabundance of ROS, the introduction of additional antioxidants is needed to return the oral cavity to a balanced state. Antioxidants are accessible from different sources, including vitamins, minerals, enzymes and hormones, as well as food and herbal supplements. Nowadays, dental manufacturers have started incorporating antioxidant formulations into toothpastes, mouth rinses/mouthwashes, lozenges, fluoride gels, dentifrices, oral sprays, and other dental products for the control of gingival and periodontal diseases¹². This review will give an update on various antioxidants, their role in treating the oral premalignant lesions Leukoplakia (Table 1, 2 and 3) and OSF (Table 4, 5 and 6).

RESULTS

A total of twenty three studies related to leukoplakia and antioxidants were considered, among which four studies shows treatment using lycopene, three studies shows treatment using Vitamin A, seven with Beta Carotene, and other eight by combination and 13-cRA. Among all the studies, lycopene shows complete resolution and

promising results. Malignancies and recurrences were reported in patients treated with beta carotene, isotretinoin, vitamin A and vitamin C^{17, 22 and 23}. There was one study using lycopene and Biocrush 250 mg³⁰, which shows complete remission of the lesion. Biocrush (Tabin-daingmya-nan) an herbal medicine which was used in Myanmar for treating Leukoplakia, but its efficacy needs further studies. Some studies²² do not recommend the combination of beta-carotene with vitamin C for the chemoprevention of oral cancer. The database of most review and studies suggest that, Beta-carotene with ascorbic acid or alpha-tocopherol is attractive because of a lack of side effects, but the range in reported values for lesion improvement has been broad and the clinical improvement typically takes several months. Topical bleomycin, systemic 13-cis-retinoic acid, vitamin A and beta-carotene caused adverse effects of varying severity^{52, 53}. Recent Cochrane review shows that none of the treatment was effective in preventing Cancer development, which was measured in studies of three treatments: systemic vitamin A, systemic beta carotene and topical bleomycin.. The one and only thing to be considered is, regardless of response to therapy, long-term follow-up is necessary⁵⁴. Fifteen studies of OSF treated with antioxidants were selected, among which five studies shows treatment using turmeric (curcumin), four using Lycopene and six using vitamins and other antioxidants. It is evident from the studies that curcumin and lycopene holds good promise in the treatment of OSF in future and that neither has any adverse effect (Table 4 and 5). A Cochrane review was done in 2008 to assess the effectiveness of lycopene in conjunction with intralesional injections of a steroid, and pentoxifylline in combination with mouth stretching exercises along with heat application. But they provided a limited amount of unreliable data, which was due to poor methodology quality⁵⁵. Some reviews raised the point that cessation of areca nut use alone has not been studied and a minority of studies includes advice to quit the habit⁵⁶. El Khoury E has stated Curcumin conjugated silver nano particles show anti-bacterial activity. Hence these curcumin conjugated nano particles can be used as an anti-cancer agent⁵⁷. Concerns were expressed regarding the small sample size, insufficient follow up, uncertain success rates of using antioxidants and lack of adequate evaluation of antioxidants prior to marketing, which demands the need for consistency in conducting and reporting the clinical trials^{58, 59}.

Table 1
Studies showing management of Oral leukoplakia with Beta-Carotene

Author and Year	No. of patients and Dosage	Results	Adverse effects and Malignant transformation
Beta-Carotene			
H. S. Garewal, et al - 1990 ¹⁵	24 patients treated with beta-carotene at a dose of 30 mg/day for six months.	Only 2 patients (8.3%) presented a complete clinical response and 15 patients (62.5%) had partial clinical response	
S. Toma, et al - 1992 ¹⁶	23 patients treated with beta-carotene, in oral doses of 90 mg/day, for three cycles of 3 months each	Of 18 patients who completed the study, 6 (33.3%) showed complete clinical response. 5% Recurrence	
G. E. Kaugars, et al - 1994 ¹⁷	79 patients, 30 mg of betacarotene, 1000 mg of L-AA [L-ascorbic acid] and 800 IU of AT [alpha tocoferol] per day for 9months.	55.7% showed reduction in the size. Clinical improvement was observed in 90% of the patients who had reduced risk factors, compared with 48.8% of improvement in those who did not.	Squamous cell carcinoma developed in seven patients (8.9%)
Sankaranarayanan, et al - 1997 ¹⁸	Out of 110 patients 55-treatment 55-placebo 360 mg beta-carotene per week during 12 months.	Complete resolution of OL. 8 out of 15 (54%) of the patients who had a complete response presented recurrence	Observed in 5 patients, 3 with headache and 2 developed muscular pain.
T. J. Barth et al 1997 ¹⁹ .	24 Beta-carotene, vitamin E, and L-AA	In 97.5% of patients, dysplasias were diminished by use of antioxidant combinations and is more evident in patients with cessation of habit.	
Garewal, et al – 1999 ²⁰	50 patients treated with beta-carotene at a dose of 60 mg/day, for six months.	Only 2 patients (4%) demonstrated a complete clinical response. Relapses were found in 4 patients.	
Nagao, et al- 2000 ²¹	48 cases detected with oral leukoplakia (38 male:10 female) examined the fasting serum levels of retinol, alpha-tocopherol, zeaxanthin and lutein, cryptoxanthin, lycopene and carotenoids (alpha-carotene and beta-carotene) by high-performance liquid chromatography	Logistic regression analysis with leukoplakia as the dependent variable showed that high serum levels of beta-carotene were related to low risk of oral leukoplakia	
J. Jack Lee, et al - 2000 ²²	70 patients, Phase 1: 3 months Phase 2: 9 months. Phase1: isotretinoin (1.5	9/26 (34.6%), 11 /33 (33.3%), and 2/11 (18.2%) developed cancer in 3 groups	

	mg/kg) Phase 2: low dose isotretinoin (0.5 mg/kg/day) or β -carotene (30 mg/day).	with low dose isotretinoin, β -carotene, and induction.
Toru Nagao et al - 2015 ²³	46 participants were allocated randomly either to an experimental arm 10 mg /day of beta-carotene and 500 mg/day of vitamin C or placebo arm 50 mg/day of vitamin C. 5-year follow-up period as a secondary endpoint.	The overall response rate at a time of 1-year observation including CR (complete remission) and PR (partial remission) in the experimental arm was 17.4% (95% CI: 1.9–32.9%) and 4.3% (95% CI: 0–12.7%) for the placebo arm.

Table 2
Studies showing management of Oral leukoplakia with Vitamin A

Vitamin A			
Joel B. Epstein, et al-1999 ²⁴	26 (17 men and 9 women) Topical 0.05% Vitamin A (tretinoin) acid gel 4 times a day	27% of the patients had a complete clinical remission. Recurrence in 40% patients with complete remission. The mean duration of the application of vitamin A acid gel was 3.5 years in the patients with clinical improvement and 1.5 years in those with no such improvement	Lichenoid reaction: 35% Sensitivity: 19%. In 4 patients the post treatment dysplasia was increased at a mean period of 1.5 years
Piattelli, et al-1999 ²⁵	10 patients (6 male, 4 females). Patients were randomly assigned either topical 0.1% isotretinoin gel or placebo for 4 months	9 patients completed the study and all of them receiving active drug showed improvement in oral lesions and the patients receiving placebo showed no virtual change. One patient showed complete resolution of lesion, whereas rest 8 showed partial resolution	Only one patient showed bcl-2 positivity
G. A. Scardina, et al - 2006 ²⁶	Forty patients were randomly divided into two groups and the drug was administered topically at 0.05% and 0.18% of isotretinoin concentrations for 3 consecutive months	Clinical resolution was 85% in the 0.18% of isotretinoin concentrations group	No adverse topical and systemic reactions in 10 years follow up.

Table 3
Studies showing management of Oral leukoplakia with Lycopene and other vitamins.

Lycopene		
Gupta, et al - 1998 ²⁷	An interviewer-administered food frequency questionnaire Among 5018 male tobacco users, 318 were diagnosed as cases	A protective effect of tomato (contains lycopene) and ascorbic acid consumption was observed in leukoplakia

Singh, et al-2004 ²⁸	58 Group 1: 20 Group 2: 20 Group 3: 18 3 months Systemic Lycopene Group 1:4mg Group 2: 8 mg Group 3: Placebo	80%, 66.25% and 12.5% clinical resolution in 3 groups respectively.	Recurrence & Malignant transformation not reported
Zakrzewska JM-2005 ²⁹	58 patients received either 8 mg oral lycopene in two doses daily (n = 20), 4 mg oral lycopene in two doses daily (n = 18) or placebo capsules (n = 18), for a 3-month period.	The response, assessed histologically, after the 8-mg lycopene treatment was significantly better than that from 4 mg lycopene. Patients taking 4 mg lycopene also responded significantly better than those in the control group. There was no significant difference in patients taking 8 mg lycopene compared to those taking 4 mg clinically in 5 month duration	
Win Pa PaAung, et al -2013 ³⁰	72 patients were treated with 10 mg and 500 mg lycopene twice a day for 3 months, with Biocrush 250 mg, bd.	totally eradication of white patch area was seen within a month	No toxicity. Or side effects encountered.
Others			
Hong – 1986 ³¹ .	44 patients 24 treatment 20 placebo 13-cis-retinoic acid 1 to 2 mg per kilogram of body weight per day for 3 months	Follow up for 9 months Clinical resolution 67% versus 10 % in Placebo. Reversal of dysplasia in 54% versus 10% in placebo Relapse occurred in 9 of 16 patients in two to three months	Two patients: Cheilitis, facial erythema, and dryness and peeling of the skin, conjunctivitis and hypertriglyceridemia
S. Toma. P. E, et al -1992 ³² .	16 patients for 6 months treated with Oral 13-cis-retinoic Acid. The initial dose, given for 3 months, was 0.2 mg/kg/day, increasing by further 0.2 mg/kg/day in successive 3 month cycles. The maximum dosage reached 1.0mg/kg/day	Fourteen of the patients completed the trial and there was one complete response obtained at 0.4 mg/kg/day. After the retinoic acid treatment was stopped, patients were followed-up for 12 months; 2 patients showed regression of the responses after 6 and 9 months	
Benner SE, et.al 199 ³³ .	43 patients treated orally with alpha-	Patient's recorded drug calendars, as well as serum	

	tocopherol (400 IU) twice daily for 24 weeks. Follow-up was performed at 6, 12, and 24 weeks after the start of treatment to assess toxicity and response, and serum alpha-tocopherol levels	drug levels, indicated excellent patient compliance
I. W. Dimery, et al 1997 ³⁴ .	7 patients treated with 13-cRA (10 mg/day) plus an escalating dose (beginning at 800IU/day, until 2000 IU/day) for 4 months	71% complete resolution
Sankaranarayanan, et al. 1997 ³⁵ .	105 patients 50 treatment 50 placebo Systemic Isotretinoin 300.000 IU given for 12 months	52% clinical resolution. 67% recurrence. Malignant transformation not reported
FaustoChiesa, et al 2005 ³⁶ .	170 [surgically operated cases with histologically proved non carcinoma cases [121 males,49 females] 84-treated 86-control 12 months 4-HPR 200 mg/day [100 mg twice a day]	43 completed treatment at full dosage with 90% compliance. 15 recurrence and 10 new lesions in control and 15 recurrence and 4 new lesions in 4-HPR treated cases. 9 out of 43 had mild adverse effects 14 with major effects: hematologic toxicity in 7, cutaneous toxicity in 6 and gastric toxicity in one. Malignant transformation was reported in both groups.

Table 4
Studies showing management of Oral submucous fibrosis with Curcumin

Author and Year	No. of patients and Dosage	Results
Curcumin		
Deepa DA et al, 2010 ³⁷ .	48 patients were called every 15 days for 3 months during treatment and followed up for 6 months Grp I: curcumin capsules Grp II: turmeric oil Grp III: multinal tablets (control grp)	Burning sensation improvement was statistically significant in grp I and II. Curcumin showed quicker results whereas turmeric oil had long term effect on follow up evaluation Grp III showed minimal improvement.
N Agarwal et al, 2014 ³⁸ .	30 subjects Group A: >35 mm Group B: Between 30 and 35 mm Group C: Between 20 and 30 mm Group D: <20 mm Turmix (curcumin 300 mg and piperine 5 mg)	An improvement of 82.50% (33), 83.33% (5), 66.10% (39), and 71.67% (43) was seen in groups A, B, C, and D, respectively. An improvement of in mouth opening of group A -10.4 mm group B, - 1.4 mm group C, - 2.3 mm group D -6.5 mm

M Yadav et al, 2014 ³⁹ .	40 patients randomly divided into 2 groups. First group: treated with weekly intralesional injection of 4 mg Dexamethasone & 1500 I.U Hyaluronidase. Second group: by oral administration of two Curcumin tablets (Turmix 300 mg) per day for 3 months each	Complete resolution of burning sensation was noted with turmix. The mean increase in interincisal distance was 3.13 mm and 1.25 mm respectively in groups 1 &2.
V K Hazarey et al, 2015 ⁴⁰ .	30 patients Two groups: 15 patients in each group. Test group: Longvida (curcumin) lozenges of 2g daily Control group: Tenovate ointment (clobetasol propionate (0.05%) along with mouth exercises for 3 months duration and follow-up was done for 6 months.	The test group showed 5.93 (± 2.37) mm, increase in mouth opening compared to control group. In relation to VAS scale with spicy and normal food the average reduction was 64 and 77 as compared to 34 and 64 respectively in control group.
F Karjodkar et al, 2016 ⁴¹ .	129 patients treated for 3 months Grp I - 20 :Turmeric oil(100mg)+Turmeric extract(500mg) 6 tabs/day 3.6 gms, GrpII- 20: Oleoresin(120mg)+Turmeric extract(600mg) 5 tabs/day 3.6 gms GrpIII -20: Oleoresin of turmeric (50mg)+250mg of mixture of betel leaf extract+ catechu extract 6 tabs/day 0.3gms GrpIV -24: Turmeric extract + Betel leaf extract+ Catechu+ Cinnamic acid(500mg) 3 tabs/day 1.5gms Grp V- 10: Betel leaf extract(150mg) 2tabs/day 0.3gms Grp VI-10: Catechu extract(150mg) 2tabs/day 0.3gms GrpVII- 25: Turmeric extract(500mg) 3tabs/day 1.5gms	The most significant response to relief in burning sensation was within Group III Only 1 patient showed oral opening improvement of more than 15 mm Group VII (Turmeric extract (500mg) showed the most statistically significant difference between micronuclei count before and after treatment.

Table 5
Studies showing management of Oral submucous fibrosis with Lycopene

Lycopene		
Kumar et al, 2007 ⁴² .	83 participants group A, n = 21: 16 mg of lycopene daily in 2 equally divided doses group B, n = 19: 16 mg of lycopene daily in 2 equally divided doses and were given intralesional injections of betamethasone (2 1-mL ampules of 4 mg each) twice weekly group C, n = 18: placebo capsules 58 patients completed the trial	Objective measurement of mouth opening was reported to be significantly improved with an average increase of 3.4mm, 4.6mm and 0mm for groups A, B and C, respectively. Complete relief from burning sensations within 2 weeks, whereas only one patient from the placebo group reported a similar improvement.
Gowda BB et al, 2011 ⁴³ .	12 adult patients Group1: Very early case Group 2: Early cases (7 patients) Group 3: Moderately advanced cases (5patients) Each patient was given lycored twice daily for 3 months, where each	Subsequently, a definite reduction in the burning sensation and an increase in the mouth opening were noted

	capsule contained 2000 µg of lycopene. The responding patients continued to take lycopene for an additional 3 months.	
Selvam NP et al, 2013 ⁴⁴ .	45 patients divided into 3 groups consisting of 15 cases each followed up to 3 and 6 months Group A: oral lycopene 16 mg/day with biweekly intralesional steroids and hyaluronidase Group B: oral antioxidant capsules with biweekly intralesional steroids and hyaluronidase Group C: biweekly intralesional steroids and hyaluronidase alone.	The results were statistically significant between Group A and C and Group B and C. There was significant increase in mouth opening among all the 3 groups.
R K C Kopuri et al, 2016 ⁴⁵ .	30 study subjects Group A: lycopene 8 mg/day in 2 divided doses prescribed for 3 months. Group B: curcumin 800 mg/day in 2 divided doses prescribed for 3 months	There were improvements in both the groups, but significant improvements were observed in Group A.

Table 6
Studies showing management of Oral submucous fibrosis with vitamins and other antioxidants

Vitamins and others		
Maher R et al, 1997 ⁴⁶ .	117 subjects Combination of micronutrients (vitamins A, B complex, C, D, and E) and minerals (iron, calcium, copper, zinc, magnesium, and others) were prescribed for one to three years	Significant improvement in symptoms, notably intolerance to spicy food, burning sensation, and mouth opening, was observed at exit
S. Gupta et al, 2004 ⁴⁷ .	34 patients Treated with “antoxid” tablets. 1 tablet thrice daily for 6 wks. Each tablet contains beta-carotene 50 mg, Vitamin A palmitate 2500 IU, Vitamin E acetate 10 IU along with Vitamin C, zinc manganese and copper.	Decrease in mean MDA level and the increase in levels of beta-carotene were found to be statistically significant. There was increase in mouth opening and tongue protrusion measurement.
Jirge et al 2008 ⁴⁸ .	45 participants Group I: oral levamisole 50 mg three times daily Group II: oral 2 capsules of antoxid daily for six weeks Group III: oral levamisole and antoxid.	improvement of mouth opening of 7.1%, 6.7% and 8.0% in groups I, II and III, respectively with reduction in burning sensations in all study groups
R Mehrotra et al, 2013 ⁴⁹ .	64 patients Vitamin A or carotinoids Se, Zn. Fe and B Complex vitamin, Mn, Cu, Vitamin C were given and followed up for 3months	Among 64 cases of oral submucous fibrosis 36 cases improved on therapy (56.25%) No patient got complete cure by therapy and there were 16 cases who failed on therapy (25%).
P Shetty et al, 2013 ⁵⁰ .	40 patients Group A:spirulina 500 mg twice daily and biweekly intralesional steroid injection of Betamethasone 4 mg/ml for 3 months	Both the groups showed statistically significant reduction in burning sensation. Mouth opening and burning sensation was found to be statistically very highly

Group B: placebo capsules twice daily and biweekly intralesional steroid injection of Betamethasone 4 mg/ml for 3 months.	significant in favor of the spirulina group
Shwetha V et al, 2016 ⁵¹ . 60 subjects Capsule Oxitard was administered to all patients at a dose of 2 capsules twice daily for a period of 3 months	Clinical improvement in mouth opening and symptoms of burning sensation as measured by the VAS scale following oxitard therapy was significant.

CONCLUSION

According to the present review, most authors support the safety and effectiveness of using antioxidants over the oral lesions, due to its scavenging effect on free radicals. But there is much debate regarding the dosage, regime and tolerance rate of antioxidants, which requires further research. Hence we conclude that more studies are necessary in the field of dentistry, considering the following points

REFERENCES

1. Battino M, Ferreiro MS, Gallardo I, Newman HN and Bullon P. The antioxidant capacity of saliva. *J Clin Periodontol.* 2002 Mar; 29(3): 189–94.
2. Singh N, Niyogi RG, Mishra D, Sharma M, Singh D. Antioxidants in Oral Health and Diseases: Future Prospects. *IOSR-JDMS* 2013 Sept; 10(3):36-40.
3. Swathi. R. Oral Submucous fibrosis and the role of curcumin in its treatment: A review. *Int J Pharm Sci Invent.* 2015; 4(6): 7-10.
4. Van der Waal I, Schepman KP, van der Meij EH, Smeele LE. Oral leukoplakia: a clinicopathological review. *Oral Oncol.* 1997 Sept; 33(5):291–301.
5. Axell T, Pindborg JJ, Smith van der Waal I. Oral white lesions with special reference to precancerous and tobacco-related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18–21 1994. *J Oral Pathol Med.* 1996 Feb; 25(2):49–54.
6. Valko M, Leibfritz D, Mocol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. *Int J Biochem Cell Biol.* 2007 Aug; 39(1): 44-84.
7. Ritty Jeba E, Saravanan T, Balasubramanian B. Natural Antioxidants in Dentistry – Review Article. *International Journal of Dental Sciences and Research.* 2015 Jan; 3(1):20-23.
8. Nagarajappa AK, Pandya D, Sreedevi, Ravi KS. Role of Free Radicals and Common Antioxidants in Oral Health, an Update. *Br J Med & Med Res.* 2015 June; 9(4): 1-12.
9. Devasagayam T, Tilak JC, Boloor KK, Sane Ketaki S, Ghaskadbi SS, Lele RD. Free Radicals and Antioxidants in Human Health: Current Status and Future Prospects. *J Assoc Physicians India.* 2004 Oct; 52:794-804.
10. Patel VP, Chu CT. Nuclear transport, oxidative stress, and neurodegeneration. *Int J ClinExpPathol.* 2011 Mar; 4(3): 215-229.
11. Nimse SB, Pal D. Free radicals, natural antioxidants, and their reaction mechanisms. *RSC Adv.*, 2015 Mar; 5:27986-28006.
12. Motiwale T, Motiwale G, Motiwale S. Antioxidants and Oral Cancer: A Review. *International Journal of Applied Research.* 2015 June; 1(8): 324-326.
13. Kumar V, Abbas A, Fausto N, Mitchell R. *Robbins Basic Pathology.* 8th ed. Elsevier pub. 2010. p 170-71.
14. Huang D, Ou B, Prior RL. The Chemistry behind Antioxidant Capacity Assays. *J Agric Food Chem.* 2005 Mar; 53:1841- 56
15. Garewal HS, Meyskens FL Jr, Killen D, Reeves D et al. Response of oral leukoplakia to beta-carotene. *J. Clin. Oncol.* 1990 Oct 8(10):1715–20.
16. Toma S, Benso S, Albanese E et al. Treatment of oral leukoplakia with beta-carotene. *Oncology.* 1992; 49(2):77–81.
17. Kaugars GE, Silverman S Jr., Lovas JGL et al. A clinical trial of antioxidant supplements in the treatment of oral leukoplakia. *Oral Surg Oral Med Oral Pathol.* 1994 Oct; 78(4):462–8.

1. Evaluation of the combination of conventional surgical excision and the administration of postoperative antioxidants should be done.
2. Most effective combinations and the exact dosage of antioxidants with least or no adverse effects need to be studied

CONFLICT OF INTEREST

Conflict of interest declared none

18. Sankaranarayanan R, Mathew B, Varghese C et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. *Oral Oncol.* 1997 Jul; 33(4):231–236.
19. Barth TJ, Zoller J, Kubler A, Born IA, Osswald H. Redifferentiation of oral dysplastic mucosa by the application of the antioxidants betacarotene, α -tocopherol and vitamin C. *Int J Vitam Nutr Res.* 1997 Jan; 67(5):368–376.
20. Garewal HS, Katz RV, Meyskens F. β -carotene produces sustained remissions in patients with oral leukoplakia. Results of a multicenter prospective trial. *Arch Otolaryngol Head Neck Surg.* 1999 Dec; 125(12):1305–10.
21. Nagao T, Ikeda N, Warnakulasuriya S. Serum antioxidant micronutrients and the risk of oral leukoplakia among Japanese. *Oral Oncol.* 2000 Sept; 36(5):466–70.
22. Lee JJ, Hong WK, Hittleman WN, Mao L et al. Predicting Cancer Development in Oral Leukoplakia: Ten Years of Translational Research. *Clin. Cancer Res.* 2000 May; 6:1702–10.
23. Nagao T, Warnakulasuriya S, Nakamura T, Kato S, et al. Treatment of oral leukoplakia with a low-dose of beta-carotene and vitamin C supplements: A randomized controlled trial. *Int. J. Cancer.* 2015 Apr; 136 (7):1708–17.
24. Joel B, Epstein JB and Gorsky M. Topical Application of Vitamin A to Oral Leukoplakia A Clinical Case Series. *Cancer.* 1999 Sept; 86(6): 921–7.
25. Piattelli A, Fioroni M, Santinelli A, Rubini C. Bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study. *Oral Oncol.* 1999 May; 35(3):314–20.
26. Scardina GA, Carini F, Maresi E, Valenza V, Messina P. Evaluation of the clinical and histological effectiveness of isotretinoin in the therapy of oral leukoplakia—ten years of experience: is management still up to date and effective? *Methods Find Exp Clin Pharmacol.* 2006 Mar; 28(2):115–9.
27. Gupta PC, Hebert JR, Bhonsle RB, Sinor PN, et al. Dietary factors in oral leukoplakia and submucous fibrosis in a population-based case control study in Gujarat, India. *Oral Dis.* 1998 Sept; 4(3):200–6.
28. Singh M, Krishnappa R, Bagewadi A, Keluskar V. Efficacy of oral lycopene in the treatment of oral leukoplakia. *Oral Oncol.* 2004 Jul; 40(6):591–6.
29. Zakrzewska JM. Oral lycopene—an efficacious treatment for oral leukoplakia? *Evid Based Dent.* 2005 Mar; 6(1):17–8.
30. Win Pa PaAung, et.al. The use of Lycopene in Oral Potentially Malignant Disorders. *Myanmar Dental Journal.* 2013; 20(1):58–63.
31. Hong WK. 13-cis-retinoic acid in the treatment of oral leukoplakia. *N Engl J Med.* 1986 Dec; 315(24):1501–5.
32. Toma S, Mangiante PE, Margarino G, Nicolo G, Palumbo R, Progressive 13-cis-retinoic acid dosage in the treatment of oral leukoplakia. *Eur J Cancer B Oral Oncol.* 1992 Oct; 28B (2):121–3.
33. Benner SE, Winn RJ, Lippman SM, Poland J, et al. Regression of oral leukoplakia with alpha-tocopherol: a community clinical oncology program chemoprevention study. *J Natl Cancer Inst.* 1993 Jan; 85(1):44–7.
34. Dimery IW, Hong WK, Lee JJ, Guillory-Perez C, Pham F, Fritzsche HA Jr, Lippman SM. Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity. *Ann Oncol.* 1997 Jan; 8(1): 85–89.
35. Sankaranarayanan R, Mathew B, Varghese C, Sudhakaran PR, Menon V, Jayadeep A, Nair MK, Mathews C, Mahalingam TR, Balaram P, Nair PP. Chemoprevention of oral leukoplakia with vitamin A and betacarotene: an assessment. *Oral Oncol.* 1997 Jul; 33(4): 231–236.
36. Chiesa F, Tradati N, Grigolato R, Boracchi P, Biganzoli E, Crose N, Cavadini E, Formelli F, Costa L, Giardini R, Zurruda S, Costa A, De Palo G, Veronesi U. Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: Long-term results. *Int. J. Cancer.* 2005 Feb; 115: 625–629.
37. Deepa DA, Balan A, Shreelata KT. Comparative study of efficacy of curcumin and turmeric oil as chemo preventive agents in oral submucous fibrosis. A clinical and histological evaluation. *J Indian Acad Oral Med Radiol.* 2010; 22(2):88:92.
38. Agarwal N, Singh D, Sinha A, Srivastava S, et al. Evaluation of efficacy of turmeric in management of oral submucous fibrosis. *J Indian Acad Oral Med Radiol* 2014 Nov; 26(3):260–263.
39. Yadav M, Aravinda K, Saxena VS, Srinivas K, Ratnakar P, Gupta J, Sachdev AS,

Shivhare P. Comparison of curcumin with intralesional steroid injections in Oral Submucous Fibrosis – A randomized, open-label interventional study. *J Oral Biol Craniofac Res.* 2014 Sept-Dec; 4(3): 169–73.

40. Hazarey VK¹, Sakrikar AR¹, Ganvir SM. Efficacy of curcumin in the treatment for oral submucous fibrosis - A randomized clinical trial. *J Oral Maxillofac Pathol.* 2015 May-Aug; 19(2): 145–52.

41. Karjodkar F, Maideo A, Sansare K, et al. Efficacy of Ayurvedic Medications for Treatment of Oral Submucous Fibrosis. *European j. biomed. pharm. sci.* 2016; 3(5): 611-618.

42. Kumar A, Bagewadi A, Keluskar V, Singh M. Efficacy of lycopene in the management of oral submucous fibrosis. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2007 Feb;103(2):207-13.

43. Gowda BB, Yathish TR, Sinhasan SP, Kumar NH, Somayaji P. The response of lycopene to oral submucous fibrosis-A carotenoid antioxidant: A clinicopathological study. *J Clin Diagn Res.* 2011 Aug; 5(3):36-41.

44. Selvam NP, Dayanand AA. Lycopene in the management of oral submucous fibrosis. *Asian J Pharm Clin Res* 2013; 6(3):58-61.

45. Kopuri RKC,Chakravarthy C, Sunder S, et al. A Comparative Study of the Clinical Efficacy of Lycopene and Curcumin in the Treatment of Oral Submucous Fibrosis using Ultrasonography. *J Int Oral Health.* 2016 Apr; 8(6):687-691.

46. Maher R, Aga P, Johnson NW, Sankaranarayanan R, Warnakulasuriya S. Evaluation of multiple micronutrient supplementations in the management of oral submucous fibrosis in Karachi, Pakistan. *Nutr Cancer.* 1997 Aug; 27(1):41-7.

47. Gupta S, Reddy MVR, Harinath BC. Role of Oxidative Stress and Antioxidants in Aetiopathogenesis and Management of Oral Submucous Fibrosis. *Indian J Clin Biochem.* 2004 Jan; 19 (1): 138-141.

48. V Jirge V, Shashikanth MC, Ali IM, Anshumalee N. Levamisole and antioxidants in the management of oral submucous fibrosis: A comparative study. *Journal of Indian Academy of Oral Medicine & Radiology.* 2008 Jun; 20(4): 135-140.

49. Mehrotra R, Nigam SK, Nigam N. Role of Antioxidants on Oral Submucous Fibrosis: A Clinico-Pathological Study. *Journal of Evolution of Medical and Dental Sciences.* 2013 Nov; vol 2, 47(25): 9174-83.

50. Shetty P, Shenai P, Chatra L, Rao PK. Efficacy of spirulina as an antioxidant adjuvant to corticosteroid injection in management of oral submucous fibrosis. *Indian J. Dent. Res.* 2013 May-Jun; 24(3): 347-50.

51. Shwetha V, Yashoda Devi B K. Efficacy and Safety Assessment of Oxitard, an Herbal Antioxidant in Oral Submucous Fibrosis-An Observational Clinical Study. *Indian Journal of Medical Research and Pharmaceutical Sciences.* 2016 Jul; 3(7): 48-53.

52. Epstein JB, Wong FL, Millner A, Le ND. Topical bleomycin treatment of oral leukoplakia: a randomized double-blind clinical trial. *Head Neck.* 1994 Nov-Dec; 16:539–544.

53. Sankaranarayanan R, Mathew B, Varghese C, et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. *Oral Oncol.* 1997 Jul; 33:231–236.

54. Lodi G, Franchini R, et.al. Highlighted review: Interventions for treating oral leukoplakia to prevent oral cancer. *Cochrane Database Syst Rev.* 2016 Jul 29;7:CD001829.

55. Fedorowicz Z1, Chan Shih-Yen E, et al. Interventions for the management of oral submucous fibrosis. *Cochrane Database Syst Rev.* 2008 Oct 8;(4):CD007156

56. Kerr AR, Warnakulasuriya S, Mighell AJ, et al. A systematic review of medical interventions for oral submucous fibrosis, and future research opportunities. *Oral Dis.* 2011 Apr; 17(1): 42–57.

57. El Khoury E, Abiad M, Kassaify ZG, Patra D. Green synthesis of curcumin conjugated nanosilver for the applications in nucleic acid sensing and antibacterial activity. *Colloids Surf B Biointerfaces.* 2015 Mar; 7(127C):274-80.

58. Schepman KP, van der Meij EH, Smeele LE, et al. Malignant transformation of oral leukoplakia: a follow-up study of a hospital based population of 166 patients with oral leukoplakia from the Netherlands. *Oral Oncol.* 1998 Jul; 34 (4):270–5.

59. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. *Cochrane Database Syst Rev.* 2012 Mar 14;(3):CD007176..